A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase 3 study to evaluate efficacy and safety of HCP1401

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited
• Treatments: Amlodipine; Chlorthalidone; Losartan

Criteria

Inclusion Criteria:

• Hypertension patient who satisfied below condition at Visit 1.

• patient who takes antihypertensive drug

• 140mmHg <= sitSBP <= 200mmHg

• patient who doesn't take antihypertensive drug

• 160mmHg <= sitSBP <= 200mmHg

• 140mmHg <= sitSBP <= 200mmHg at Visit 2

Exclusion Criteria:

• Patient who have received 4 or more antihypertensive drug

• Patient with 20mmHg of difference in sitSBP or 10mmHg of difference in sitDBP between 3 times of BP measuring at Visit 1

• Patient with sitDBP >= 120mmHg at Visit 2

• Patient with secondary hypertension